Latest Breaking News On - Frederic ors - Page 1 : comparemela.com

Press release content from Business Wire. The AP news staff was not involved in its creation. IMV’s Lead Immunotherapy to be Investigated in Breast Cancer May 10, 2021 GMT DARTMOUTH, Nova Scotia (BUSINESS WIRE) May 10, 2021 IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies, today announced that its lead compound, maveropepimut-S (DPX-Survivac) will be investigated in patients with hormone receptor positive/HER2-negative (HR+/HER2-) breast cancer. HR+/HER2- tumors represent an unmet clinical need with relatively poor responses to neoadjuvant endocrine treatment 1. This investigator-initiated clinical study will be conducted at the Providence Cancer Institute in Portland, Oregon, and is expected to begin during summer 2021.

United statesKristinah youngSashae stantonMerck keytrudaRelationsmarc jasminCancer immunoprevention lab at providenceNational cancer instituteJoseph healthEarlea chiles research instituteTumor microenvironment labRobertw franz cancer centerEuropean medicines agencyProvidence cancer instituteProvidence cancer institute in portlandFrederic orsChief executive officer